Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial.
According to Adial, as part of its Phase 3 trial preparation, it has partnered with closely held Cytel to provide expert support on trial design and interrogation, advancing statistical analytics and simulation modeling. The Phase 3 trial is expected to commence in late 2025.
In a previous statement, the company reported that AD04 represents a first-in-class opportunity in the multi-billion-dollar global AUD market and that its refined clinical strategy will accelerate value realization.
